LIBRETTO-431 study: Lilly’s Retevmo emerges as potential first-line treatment for RET fusion-positive NSCLC

Pallavi Madhiraju- August 6, 2023 0

Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the assessment of Retevmo against platinum-based chemotherapy plus ... Read More

Eagle Pharmaceuticals gets Pemfexy FDA approval for NSCLC

Raghuram Kadari- December 28, 2022 0

Eagle Pharmaceuticals has secured an additional indication for Pemfexy (pemetrexed injection) in the US, marking the fifth indication for the intravenous medication. Pemfexy in combination ... Read More

Lantern Pharma gets FDA nod for Harmonic phase 2 clinical trial of LP-300

pallavi123- July 17, 2022 0

Lantern Pharma said that the US Food and Drug Administration (FDA) has authorized it to move ahead with its Harmonic phase 2 clinical trial of ... Read More

Dr. Reddy’s Laboratories launches Pemetrexed for Injection

pallavi123- May 27, 2022 0

Dr. Reddy’s Laboratories said that it has launched Pemetrexed for Injection, 100 mg and 500 mg single-dose vials in the US market. Pemetrexed for Injection ... Read More

FDA rejects Lilly’s sintilimab as first line treatment of NSCLC

pallavi123- March 27, 2022 0

The US Food and Drug Administration (FDA) has rejected the biologics license application (BLA) of Eli Lilly and Company (Lilly)’s sintilimab injection in nonsquamous non-small ... Read More

Zydus Cadila gets FDA nod for chemotherapy drug Pemetrexed generic

pallavi123- June 28, 2021 0

Cadila Healthcare (also known as Zydus Cadila) said that it has secured tentative approval from the US Food and Drug Administration (FDA) for marketing Pemetrexed ... Read More